Altogether, these results disclosed for the first time that the anti-tumor activity of regorafenib as a second-line drug for advanced HCC also relies on the FOXO3-induced cytoprotective autophagy inhibition, thereby supporting the involvement of this pro-survival mechanism in the sorafenib resistance acquisition. This evidence concerns the gene FOXO3 and hepatocellular carcinoma.